Bacterial flora in inflammatory bowel disease

Digestive Diseases

Volumn 27, Issue SUPPL. 1, 2010, Pages 99-103

  Marteau, Philippe ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bacteria; Crohn's disease; Inflammatory bowel disease; Pathogenesis; Ulcerative colitis

Indexed keywords

CIPROFLOXACIN; METRONIDAZOLE; TOLL LIKE RECEPTOR;

BACTERIAL FLORA; CONFERENCE PAPER; CROHN DISEASE; CYTOPLASM; ENTERITIS; ESCHERICHIA COLI; FIRMICUTES; HOST CELL; HUMAN; ILEITIS; IMMUNE RESPONSE; IN SITU HYBRIDIZATION; IN VITRO STUDY; INTESTINE BIOPSY; INTESTINE MUCOSA; MELANOSIS; MICROFLORA; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; BACTERIA; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINES; METAGENOME;

EID: 77950839548     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000268128     Document Type: Conference Paper

References (48)

1. Crohn BB, Ginzburg L, Oppenheimer GD: Regional ileitis: a pathologic and clinical entity. JAMA 1932; 99: 1323-1329.
2. Packey CD, Sartor RB: Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med 2008; 263: 597-606.
3. Noomen CG, Hommes DW, Fidder HH: Update on genetics in inflammatory disease. Best Pract Res Clin Gastroenterol 2009; 23: 233-243.
4. Naser SA, Ghobrial G, Romero C, Valentine JF: Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004; 364: 1039-1044.
5. Bentley RW, Keenan JI, Gearry RB, Kennedy MA, Barclay ML, Roberts RL: Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. Am J Gastroenterol 2008; 103: 1168-1172.
6. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421.
7. Martinez-Medina M, Aldeguer X, Lopez- Siles M, González-Huix F, López-Oliu C, Dahbi G, Blanco JE, Blanco J, Garcia-Gil LJ, Darfeuille-Michaud A: Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm Bowel Dis 2009; 15: 872-882.
8. Laharie D, Asencio C, Asselineau J, Bulois P, Bourreille A, Moreau J, Bonjean P, Lamarque D, Pariente A, Soulé JC, Charachon A, Coffin B, Perez P, Mégraud F, Zerbib F: Association between entero-hepatic Helicobacter species and Crohn's disease: a prospective cross-sectional study. Aliment Pharmacol Ther 2009; 30: 283-293.
9. Issa M, Ananthakrishnan AN, Binion DG: Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1432-1442.
10. Hugot JP, Alberti C, Berrebi D, Bingen E, Cézard JP: Crohn's disease: the cold chain hypothesis. Lancet 2003; 362: 2012-2015.
11. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N: Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79-83.
12. Minami M, Ando T, Okamoto A, Sasaki N, Ohkura T, Torii K, Hasegawa T, Ohta M, Goto H: Seroprevalence of Fusobacterium varium in ulcerative colitis patients in Japan. FEMS Immunol Med Microbiol 2009; 56: 67-72.
13. Llopis M, Antolin M, Guarner F, Salas A, Malagelada JR: Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut 2005; 54: 955-959.
14. Heuvelin E, Lebreton C, Grangette C, Pot B, Cerf-Bensussan N, Heyman M: Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors. PLoS One 2009; 4:e5184.
15. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez- Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
16. Sokol H, Seksik P, Furet JP, Firmesse O, Nion- Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J: Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15: 1183-1189.
17. Mangin I, Bonnet R, Seksik P, Rigottier-Gois L, Sutren M, Bouhnik Y, Neut C, Collins MD, Colombel JF, Marteau P, Doré J: Molecular inventory of faecal microflora in patients with Crohn's disease. FEMS Microbiol Ecol 2004; 50: 25-36.
18. Marteau P, Pochart P, Doré J, Béra-Maillet C, Bernalier A, Corthier G: Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol 2001; 67: 4939-4942.
19. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43: 3380-3389.
20. Zoetendal EG, Akkermans AD, De Vos WM: Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998; 64: 3854-3859.
21. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al: Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-242.
22. Maukonen J, Satokari R, Mättö J, Söderlund H, Mattila-Sandholm T, Saarela M: Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006; 55: 625-633.
23. Scanlan PD, Shanahan F, O'Mahony C, Marchesi JR: Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol 2006; 44: 3980-3988, erratum in J Clin Microbiol 2007; 45: 1671.
24. De La Cochetière MF, Durand T, Lepage P, Bourreille A, Galmiche JP, Doré J: Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J Clin Microbiol 2005; 43: 5588-5592.
25. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E, Muñoz-Tamayo R, Paslier DL, Nalin R, Dore J, Leclerc M: Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009; 11: 2574-2584.
26. Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, Guarner F, Malagelada JR: Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 2008; 103: 643-648.
27. Tamboli CP, Neut C, Desreumaux P, Colombel JF: Dysbiosis as a prerequisite for IBD. Gut 2004; 53: 1057.
28. Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y: Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008; 14: 147-161.
29. Lay C, Rigottier-Gois L, Holmstrøm K, Rajilic M, Vaughan EE, de Vos WM, Collins MD, Thiel R, Namsolleck P, Blaut M, Doré J: Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol 2005; 71: 4153-4155.
30. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW: Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 2007; 1: 403-418.
31. Sasaki M, Sitaraman SV, Babbin BA, Gerner- Smidt P, Ribot EM, Garrett N, Alpern JA, Akyildiz A, Theiss AL, Nusrat A, Klapproth JM: Invasive Escherichia coli are a feature of Crohn's disease. Lab Invest 2007; 87: 1042-1054.
32. Rhodes JM: The role of Escherichia coli in inflammatory bowel disease. Gut 2007; 56: 610-612.
33. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Dore J: Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 106-111.
34. Kotlowski R, Bernstein CN, Sepehri S, Krause DO: High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007; 56: 669-675.
35. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J: Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55: 205-211.
36. Mangin I, Bonnet R, Seksik P, Rigottier-Gois L, Sutren M, Bouhnik Y, Neut C, Collins MD, Colombel JF, Marteau P, Doré J: Molecular inventory of faecal microflora in patients with Crohn's disease. FEMS Microbiol Ecol 2004; 50: 25-36.
37. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Dore J: Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 106-111.
38. Zoetendal EG, von Wright A, Vilpponen- Salmela T, Ben-Amor K, Akkermans AD, de Vos WM: Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002; 68: 3401-3407.
39. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
40. Lepage P, Seksik P, Sutren M, de la Cochetiere MF, Jian R, Marteau P, et al: Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis 2005; 11: 473-480.
41. Vasquez N, Mangin I, Lepage P, Seksik P, Duong JP, Blum S, Schiffrin E, Suau A, Allez M, Vernier G, Tréton X, Doré J, Marteau P, Pochart P: Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria: a study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresis. Inflamm Bowel Dis 2007; 13: 684-692.
42. Seksik P, Lepage P, de la Cochetiere MF, Bourreille A, Sutren M, Galmiche JP, et al: Search for localized dysbiosis in Crohn's disease ulcerations by temporal temperature gradient gel electrophoresis of 16S rRNA. J Clin Microbiol 2005; 43: 4654-4658.
43. Sokol H, Vasquez N, Hoyeau N, Seksik P, Beaugerie L, Lavergne-Slove A, Pochart P, Marteau P: Crypt abscess associated microbiota in inflammatory bowel disease and acute self-limited colitis. World J Gastroenterol, in press.
44. Carvalho FA, Barnich N, Sivignon A, Darcha C, Chan CH, Stanners CP, Darfeuille-Michaud A: Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med 2009; 206: 2179-2189.
45. Malchow HA: Crohn's disease and Escherichia coli . A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25: 653-658.
46. Travis SPL, Stange EF, Lemann M, et al: European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62.
47. Sans M: Probiotics for inflammatory bowel disease: a critical appraisal. Dig Dis 2009; 27(suppl 1):111-114.
48. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al: Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861.